Clinical significance and future prospect of RESOLVE study on neoadjuvant chemotherapy for gastric cancer in China

RESOLVE study is an open, multicenter, randomized, controlled clinical phase 3 study, aimed at providing perioperative treatment for advanced gastric cancer in Chinese population. This study included cT₄ patients, compared the efficacy of SOX (oxaliplatin + teggio) adjuvant chemotherapy with CapOx (oxaliplatin + capecitabine) adjuvant chemotherapy, SOX neoadjuvant chemotherapy and CapOx adjuvant chemotherapy, and confirmed the superiority of SOX neoadjuvant chemotherapy for advanced gastric cancer. The RESOLVE study is a good start for the research on the perioperative treatment scheme in Chinese patients with advanced gastric cancer. However, this study and the international large-scale studies MAGIC and FLOT4 are not the direct comparison of neoadjuvant and adjuvant therapy based on the same chemotherapy drugs. The forward clinical researches of the more accurate perioperative treatment scheme for advanced gastric cancer based on the tissue classification and genotyping would be expected.